Show Summary Details
Page of

Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial 

Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial
Chapter:
Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial
Author(s):

Robert J. Claycomb

DOI:
10.1093/med/9780199377527.003.0014
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 October 2019

This chapter provides a summary of a landmark study in multiple sclerosis. Is natalizumab in combination with interferon therapy associated with fewer relapses in patients with relapsing-remitting multiple sclerosis when compared to interferon therapy alone? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. Natalizumab in addition to interferon beta-1a therapy was found to be associated with a slower progression of relapsing-remitting multiple sclerosis. However, the use of natalizumab in combination with interferon beta-1a was associated with progressive multifocal leukoencephalopathy. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.